Treatment Innovations

Bridging the Gap: FDA Expands Tivicay PD Label to Include HIV-Positive Newborns

• Treatment Innovations

Bridging the Gap: FDA Expands Tivicay PD Label to Include HIV-Positive Newborns

Rifan Muazin September 17, 2026

In a landmark development for pediatric medicine, the U.S. Food and Drug Administration (FDA) has officially approved...

Read More Read more about Bridging the Gap: FDA Expands Tivicay PD Label to Include HIV-Positive Newborns

Redefining the Future of Pharma: PharmSci 360 to Tackle Research Integrity and the Post-Animal Era

• Treatment Innovations

Redefining the Future of Pharma: PharmSci 360 to Tackle Research Integrity and the Post-Animal Era

Neng Nana September 16, 2026

As the pharmaceutical industry stands at the precipice of a technological revolution, the American Association of Pharmaceutical...

Read More Read more about Redefining the Future of Pharma: PharmSci 360 to Tackle Research Integrity and the Post-Animal Era

Bridging the Diagnostic Gap: Evvy Secures $40M to Revolutionize Women’s Health Through AI and Microbiome Science

• Treatment Innovations

Bridging the Diagnostic Gap: Evvy Secures $40M to Revolutionize Women’s Health Through AI and Microbiome Science

Raul Delapena Setiawan September 16, 2026

In a landmark development for the FemTech sector, Evvy, a pioneering health-technology firm, has successfully closed an...

Read More Read more about Bridging the Diagnostic Gap: Evvy Secures $40M to Revolutionize Women’s Health Through AI and Microbiome Science

Pivot Point: Cellectis Abandons Allogeneic Cell Therapy Ambitions for Cardiovascular Gene Editing

• Treatment Innovations

Pivot Point: Cellectis Abandons Allogeneic Cell Therapy Ambitions for Cardiovascular Gene Editing

Nana Wu September 16, 2026

By Jonathan Gardner | Published September 14, 2026 In a decisive move that signals a fundamental retreat...

Read More Read more about Pivot Point: Cellectis Abandons Allogeneic Cell Therapy Ambitions for Cardiovascular Gene Editing

Bridging the Gap: Gilead and Nucleai Harness AI to Solve the ADC Resistance Paradox

• Treatment Innovations

Bridging the Gap: Gilead and Nucleai Harness AI to Solve the ADC Resistance Paradox

Muslim September 16, 2026

The landscape of modern oncology is currently dominated by a singular, high-stakes ambition: the refinement of antibody-drug...

Read More Read more about Bridging the Gap: Gilead and Nucleai Harness AI to Solve the ADC Resistance Paradox

The Governance Gap: Navigating the Rise of Agentic AI in Modern Healthcare

• Treatment Innovations

The Governance Gap: Navigating the Rise of Agentic AI in Modern Healthcare

Ali Ikhwan September 16, 2026

As the healthcare industry stands on the precipice of a digital transformation, the integration of Artificial Intelligence...

Read More Read more about The Governance Gap: Navigating the Rise of Agentic AI in Modern Healthcare

The Race for Innovation: FDA Launches “Operation Trialblazer” to Stem the Tide of Overseas Clinical Trials

• Treatment Innovations

The Race for Innovation: FDA Launches “Operation Trialblazer” to Stem the Tide of Overseas Clinical Trials

Nana September 16, 2026

In a strategic move to reclaim its status as the world’s premier hub for pharmaceutical innovation, the...

Read More Read more about The Race for Innovation: FDA Launches “Operation Trialblazer” to Stem the Tide of Overseas Clinical Trials

A Potential Breakthrough: Psilocybin Shows Promise in Preventing Chemotherapy-Induced Nerve Damage

• Treatment Innovations

A Potential Breakthrough: Psilocybin Shows Promise in Preventing Chemotherapy-Induced Nerve Damage

Azzam Bilal Chamdy September 16, 2026

For decades, the field of oncology has faced a stubborn, disabling challenge: chemotherapy-induced peripheral neuropathy (CIPN). While...

Read More Read more about A Potential Breakthrough: Psilocybin Shows Promise in Preventing Chemotherapy-Induced Nerve Damage

The Shifting Sands of Biotech: Radiopharmaceutical Milestones and Corporate Pivots

• Treatment Innovations

The Shifting Sands of Biotech: Radiopharmaceutical Milestones and Corporate Pivots

Jia Lissa September 16, 2026

The biopharmaceutical landscape has undergone a week of seismic shifts, characterized by historic regulatory breakthroughs, high-stakes corporate...

Read More Read more about The Shifting Sands of Biotech: Radiopharmaceutical Milestones and Corporate Pivots

The Frontier of Lung Cancer: Breakthroughs, Geographic Disparities, and the ADC Revolution

• Treatment Innovations

The Frontier of Lung Cancer: Breakthroughs, Geographic Disparities, and the ADC Revolution

Suro Senen September 15, 2026

The annual World Conference on Lung Cancer (WCLC) serves as the definitive global barometer for oncology, offering...

Read More Read more about The Frontier of Lung Cancer: Breakthroughs, Geographic Disparities, and the ADC Revolution